Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKinsey
Medtronic
AstraZeneca
Express Scripts

Last Updated: August 19, 2022

Investigational Drug Information for Masitinib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Masitinib?

Masitinib is an investigational drug.

There have been 36 clinical trials for Masitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 25th 2008.

The most common disease conditions in clinical trials are Sclerosis, Mastocytosis, and Gastrointestinal Stromal Tumors. The leading clinical trial sponsors are AB Science and [disabled in preview].

Recent Clinical Trials for Masitinib
TitleSponsorPhase
Masitinib for the Treatment of Severe Mast Cell Activation SyndromeAB SciencePhase 2
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple SclerosisAB SciencePhase 3
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19AB SciencePhase 2

See all Masitinib clinical trials

Clinical Trial Summary for Masitinib

Top disease conditions for Masitinib
Top clinical trial sponsors for Masitinib

See all Masitinib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKinsey
Medtronic
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.